Accuracy Coverage Pricing Contact

Dechra increases its 2019 interim dividend by 29.6%

Investment Tools Ltd.
Dechra increases its 2019 interim dividend by 29.6%

Highlights

·     Trading in the Period was strong and in line with management expectations.

·     Reported Group revenue for the Period increased by 19.1% at Constant Exchange Rate (CER) (19.2% at Actual Exchange Rate (AER)).

·     European Pharmaceuticals (EU Pharmaceuticals) revenue growth was 18.9% at CER (18.1% at AER).

·     North American Pharmaceuticals (NA Pharmaceuticals) revenue growth was 19.3% at CER (21.0% at AER).

·     Underlying operating profit growth was 28.0% at CER (28.2% at AER) with operating margin expansion of 190 bps to 26.3%.

·     Reported operating profit declined mainly due to increased amortisation of the acquired intangibles.

·     Strong cash conversion of 110.0% driven by the expected unwinding of working capital.

·     AST Farma, Le Vet, RxVet and Caledonian acquisitions performing well and in line with our expectations; acquisition of Laboratorios Vencofarma do Brasil Ltda (Venco) completed.

·     Underlying diluted EPS growth of 11.4% to 41.76 pence. Interim dividend increased by 29.6% to 9.5 pence.

Companies mentioned

Latest News

Investment Tools Limited
Investment Tools Limited
Investment Tools Limited

Workspace 2019 interim results

Read more
Investment Tools Limited

Avon Rubber 2018 final results

Read more
Investment Tools Limited

Adept technology 2019 interim results

Read more
Investment Tools Limited

Land Securities 2018 interim results

Read more
Investment Tools Limited

DCC 2019 interim results

Read more
Investment Tools Limited

B&M European value retail 2019 interim results

Read more
Investment Tools Limited

Softcat 2018 final results

Read more
Investment Tools Limited

Bellway 2018 final results

Read more
More News